Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Ltd. reports dosing the first patient at a United States clinical site in its global Phase 2b trial of Allocetra™ for moderate-to-severe age-related primary knee osteoarthritis. This marks the start of U.S. enrollment in a randomized, double-blind, placebo-controlled study.
The multicenter trial spans sites in the United States, Denmark and Poland and evaluates intra-articular Allocetra™ injections. Key efficacy measures track pain and physical function at three and six months, with additional quality-of-life and mobility endpoints. Enlivex positions Allocetra™ within a broader strategy that combines longevity-focused immunotherapy development with a prediction markets treasury built around the Rain protocol.
Enlivex Ltd. reports it has received a Nasdaq notice that its ordinary shares failed to meet the $1.00 minimum bid price requirement for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days, until November 9, 2026, to regain compliance by having a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. If it meets other listing standards, Enlivex may qualify for an additional 180‑day period, after which its shares could face delisting if compliance is not restored. The notice does not immediately affect the listing or trading of Enlivex’s shares or its business operations.
Enlivex Ltd. registers 23,333,333 ordinary shares for resale by a selling shareholder pursuant to a senior secured convertible promissory note. The shares are issuable under the Note and represent the company’s good-faith estimate of the maximum Note Conversion Shares. The company will receive no proceeds from resales; net proceeds go to the selling shareholder.
Enlivex Ltd. filed a Form F-3 shelf prospectus to register up to 23,333,333 ordinary shares for resale by a selling shareholder. These shares are issuable upon conversion or repayment of a $21.0 million senior secured convertible promissory note issued in a private placement that closed on March 23, 2026.
The Note was purchased for $19.0 million, matures on March 23, 2027, and has an initial conversion price of $2.69175 per share. The company will not receive proceeds from resales; net proceeds go to the selling shareholder. The registration permits resale "from time to time" once the statement is declared effective.
Enlivex Ltd. reports that Denmark’s medicines regulator has approved its Clinical Trial Application for a Phase 2b trial of Allocetra™ in moderate-to-severe age-related primary knee osteoarthritis. This follows recent FDA clearance and supports a global, randomized, double-blind, placebo-controlled study enrolling patients in the United States, Denmark and Poland.
The trial will test intra-articular injections of Allocetra™ with key efficacy endpoints focused on pain and physical function at three and six months, plus quality-of-life and mobility measures. Enlivex also highlights its dual focus on developing Allocetra™ for inflammatory, aging-related conditions and operating a prediction markets treasury strategy built around the Rain protocol.
Enlivex Ltd. reports that Ondo Finance has launched ENLVon, a tokenized representation of Enlivex’s ordinary shares on Ondo’s Global Markets platform. This structure lets non-U.S. retail and institutional investors gain economic exposure to Enlivex through blockchain-based digital infrastructure.
ENLVon can be held in compatible digital wallets, transferred subject to platform and regulatory requirements, and used within a growing ecosystem of financial applications, including as collateral or in lending and yield strategies. The model supports fractional exposure with low minimum investment and near‑instant settlement, aligning Enlivex with the expanding tokenized securities market.
Enlivex Ltd. reported that the Rain Foundation, which oversees the decentralized Rain prediction markets protocol, has launched an AI agent-ready interface and a $5 million grant program. The initiative aims to help developers and creators build, launch, and monetize independent prediction market platforms via AI agents such as OpenClaw.
Enlivex’s CEO highlighted that the company is a major holder of the RAIN token and views Rain’s new single‑prompt market creation as a forward-looking concept. The company believes future revenue growth of the Rain protocol and the appropriation of approximately 2.5% of total trading volume to automatic RAIN token buy-and-burn could benefit RAIN’s value and support Enlivex’s digital asset treasury strategy.
Enlivex Ltd. files its Annual Report on Form 20-F for the year ended December 31, 2025, outlining a dual strategy that combines clinical-stage immunotherapy with a crypto-based treasury model. The company is developing Allocetra™, an off-the-shelf cell therapy targeting osteoarthritis and other inflammatory conditions by reprogramming macrophages to a homeostatic state.
Enlivex has established a digital asset treasury centered on the RAIN governance token, acquired using $212 million of gross proceeds from a November 24, 2025 private placement. The report warns that fair value accounting for these digital assets under ASU 2023-08 could create significant volatility in reported earnings and the carrying value of its crypto holdings.
The company has incurred operating losses since inception, has retained earnings of approximately $1.1 billion as of December 31, 2025, and has not generated product revenue. Management expects existing resources to fund planned operations, including product development, through the end of 2027, but highlights the need for substantial additional capital thereafter and notes that its ability to continue as a going concern depends on securing further financing. Extensive risk factors are detailed, including clinical, regulatory, manufacturing, competitive, cybersecurity, product liability and ESG-related risks, as well as risks from cryptocurrency market volatility and evolving digital asset regulation.
Enlivex Ltd. reported a strong turnaround for the year ended December 31, 2025, with net income of $1.23 billion and diluted earnings per ordinary share of $25.48. Management explains that these earnings were driven primarily by appreciation in the value of its treasury and treasury-related derivative assets.
The company describes itself as a quality longevity business powered by a prediction markets treasury. Its dual strategy pairs development of Allocetra™, an immunotherapy targeting inflammatory conditions of aging such as age-related osteoarthritis, with a treasury model built around the RAIN decentralized prediction markets protocol.
Enlivex is hosting an earnings webcast at 09:00 am Eastern Time to discuss these results and its outlook, available via online registration and through the investor relations section of its website.